GlassScriptPhysician profile
Sara Hunsicker
NPI 1245853183
$4,652.37
in general payments reported to CMS, 2019-2025
35 companies · $4,652 in 2025
The $4,652 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,988 · Travel and Lodging: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.26 |
| Travel and Lodging | $664.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,308.44 | 2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $491.98 | 2025 | |
| Pfizer INC. | $483.77 | 2025 | |
| Ucb, INC. | $250.98 | 2025 | Fintepla, Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $210.31 | 2025 | |
| Amgen INC. | $176.57 | 2025 | Uplizna |
| Janssen Biotech, INC. | $168.85 | 2025 | |
| Argenx US, INC. | $159.06 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Mallinckrodt Hospital Products INC. | $149.99 | 2025 | Acthar |
| Neurocrine Biosciences, INC. | $141.95 | 2025 | |
| Neurelis, INC. | $125.11 | 2025 | Valtoco |
| Tg Therapeutics, INC. | $120.04 | 2025 | |
| Emd Serono, INC. | $100.56 | 2025 | Mavenclad |
| Biogen, INC. | $91.15 | 2025 | Vumerity, Tysabri, Skyclarys |
| Axsome Therapeutics, INC. | $79.09 | 2025 | Symbravo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $61.57 | 2025 | Austedo Xr |
| Lundbeck LLC | $51.58 | 2025 | Vyepti |
| Springworks Therapeutics, INC. | $46.49 | 2025 | Gomekli |
| Celgene Corporation | $40.21 | 2025 | Zeposia |
| Lilly USA, LLC | $37.01 | 2025 | Kisunla |
| Vanda Pharmaceuticals INC. | $30.53 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $28.97 | 2025 | Xeomin |
| Sk Life Science, INC. | $27.15 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $26.40 | 2025 | |
| Tanabe Pharma America, INC. | $26.30 | 2025 | Radicava |
| Eisai INC. | $25.94 | 2025 | |
| Boston Scientific Corporation | $25.92 | 2025 | Vercise |
| Ani Pharmaceuticals, INC. | $25.13 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $23.69 | 2025 | Gamunex-C |
| Acadia Pharmaceuticals INC | $22.62 | 2025 | Nuplazid |
| Genzyme Corporation | $21.63 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.50 | 2025 | Ultomiris |
| Cycle Pharmaceuticals INC | $20.38 | 2025 | Bafiertam, Tascenso Odt |
| Csl Behring | $17.14 | 2025 | Hizentra |
| Amneal Pharmaceuticals LLC | $15.36 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Hunsicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.